ESR1 and breast carcinoma: Beyond discordance in ER, PR, and HER2 expression by immunohistochemistry, multiple next-generation sequencing (NGS) studies have also documented frequent shifts in intrinsic molecular subtypes in breast cancer [28,29,30,31,32].